Unmet Need: Necessity of approved therapeutics to treat ARDS (acute respiratory distress syndrome)
Acute respiratory distress syndrome (ARDS) is a life-threatening form of respiratory failure caused by widespread inflammatory damage. Trauma or infections can cause acute lung inflammation/injury (ALI) that can quickly lead to ARDS. WSU Inventors have identified a novel approach to treat lung inflammation and cancers.
The Technology: Design of DHA-loaded liposomes targeted to activated neutrophils
When DHA (docosahexaenoic acid) is delivered into activated neutrophils, it can be synthesized to form resolvins. WSU researchers have demonstrated that ionizable lipid nanoparticles loaded with DHA or chemo drugs can target inflammatory tissues. This allows DHA to produce resolvins to control inflammatory responses, while chemo drugs simultaneously kill cancer cells.
Applications:
Advantages:
Patent Information:
Provisional patent application has been filed.